Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Another common early symptom is blurry or distorted vision. Straight lines, like those on a doorframe or a tiled floor, may ...

A hospital has launched a specialist "state-of-the-art" £250,000 ophthalmology suite for eye procedures. Kettering General ...

Germany’s Formycon and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Macular neovascularization within 1 year of avacincaptad pegol therapy worsens outcomes compared with patients without ...

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration (AMD). Izervay can cause side effects that range from mild to serious. Examples ...

Regulatory ApprovalFormycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / 06:30 CET/CESTThe issuer is solely ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.